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Abstract 
 
Background: Bi-annual vitamin A supplementation is a well-established survival tool for 
preschool children six months and older in vitamin A deficient populations but this schedule 
misses the opportunity to intervene on most young infant deaths. Randomized trials of 
neonatal vitamin A supplementation (NVAS) in the first few days of life to assess its impact 
on under six month mortality in low- and middle-income countries have had varying results.  
 
Methods: Investigators of 11 published randomized placebo controlled NVAS trials 
(n=163,567 children) re-analyzed their data according to an agreed plan and pooled the 
primary outcomes of mortality from supplementation through six and 12 months of age using 
random effects models and meta-regression. One investigator withdrew but allowed use of 
the data. 
 
Findings: Overall there was no effect of NVAS on infant survival through six (Risk Ratio 
(RR) 0.97; 95% CI 0.89-1.06) or twelve months of age (RR 1.00; 95% CI 0.93-1.08) but 
results varied by study population characteristics.  
 
NVAS significantly reduced six month mortality among the trials conducted in Southern Asia 
(RR 0.87; 95% CI 0.77-0.98), in contexts with moderate or severe vitamin A deficiency 
(defined as 10% or higher proportion of women with serum retinol <0.7 µmol/L or 5% or 
more women with night blindness) (RR 0.87; 95% CI 0.80-0.94),  early infant mortality was 
30 or more per 1000 live births (RR 0.91; 95% CI 0.85-0.98), 75% or more of infant 
mortality occurred in the first six months of life (RR 0.92; 95% CI 0.84-1.01), or where  
>32% mothers had no schooling (RR 0.88; 95% CI 0.80-0.96). NVAS did not reduce 
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mortality in the first 6 months of life in trials conducted in Africa, in contexts characterized 
by a low prevalence of vitamin A deficiency, lower rates of infant mortality and where 
maternal education was more prevalent. There was a suggestion of increased infant mortality 
in trials conducted in Africa (RR 1.07; 95% CI 1.00-1.15). 
 
Individual-level characteristics such as sex, birth weight, gestational age and size, age at 
dosing, parity, time of breastfeeding initiation, maternal education and maternal vitamin A 
supplementation did not modify the impact of NVAS.  
 
Conclusion: NVAS reduced  infant mortality  in South Asia, in contexts where the prevalence 
of maternal vitamin A deficiency is moderate to severe and early infant mortality is high; but 
it had no beneficial effect on infant survival in Africa, in contexts where the prevalence of 
maternal vitamin A deficiency is lower, and early infant mortality is  low 
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WHAT IS KNOWN 
- Vitamin A supplementation of children 6-59 months in settings where the deficiency is a 
public health problem has been shown to reduce mortality.  
- Supplementation between 1 and 5 months has consistently been found as not beneficial.  
- Supplementation early in the neonatal period has been observed to reduce mortality in South 
Asia but not in Africa, for reasons that remain unclear.  
 
WHAT THIS STUDY ADDS 
-Neonatal vitamin A supplementation (NVAS) reduced infant mortality in South Asia, in 
contexts where the prevalence of maternal vitamin A deficiency was of public health 
importance.   
- NVAS reduced mortality where there was high infant mortality and high percentages of 
mothers never attending school, conditions typical of South Asian study sites. 
- No survival benefit, and possibly harm, was suggested in Africa, in contexts where maternal 
deficiency was milder, infant mortality was lower, and maternal schooling was longer.  
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INTRODUCTION 
Globally, close to 6 million children under five died in 2015; the majority of these deaths 
occurred in the first year of life.1 Despite considerable progress in reducing child mortality 
over the past decade, new interventions are needed to accelerate improvements in child 
survival. 
Maternal and child under nutrition is a major risk factor for child mortality, accounting for 
nearly half of all under-five deaths.2 Neonatal vitamin A supplementation (NVAS) has been 
considered as a potential intervention to reduce infant mortality. This expectation was based 
on the benefits of vitamin A supplementation from 6 months of age in reducing later infant 
mortality and plausible biological mechanisms by which this could occur, in addition to the 
observation of widespread maternal vitamin A deficiency in some regions of the world. The 
World Health Organization (WHO) recommends periodic vitamin A supplementation for 
children aged six to 59 months. It has been shown to reduce mortality by 12-30% 3-6 and has 
been implemented in more than 100 countries worldwide.7 However, trials assessing the 
effect of supplementation in one to five month old infants suggest there is no benefit of 
supplementation in this age group.8-11 Initial randomized trials of NVAS showed mixed 
results regarding their effects on improving survival. Trials in Indonesia, Bangladesh, and 
India found significant reductions in  mortality during the first year of life12-14, while a small 
trial from Nepal10, a trial conducted in Zimbabwe 15,16, and three trials carried out in Guinea-
Bissau17-19 found no evidence of benefit. Two meta-analyses published in 2011 identified the 
same seven randomized controlled trials12-18, but reached different conclusions about the 
effects of NVAS on infant survival.20,21 
WHO convened a technical consultation in December 2008 to review the existing evidence 
regarding NVAS. The technical consultation concluded that there was insufficient evidence 
to inform public health policy. Three additional randomized trials were commissioned 
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following its recommendations. The publication of these large trials conducted in Ghana, 
India, and Tanzania added substantially to the evidence base.  While the trial conducted in 
India found a ten percent reduction in mortality through to six months after 
supplementation22, the trials in Ghana and Tanzania found no survival benefit.23,24  The 
results of these trials were reviewed in the context of pre-existing trials at a technical 
consultation led by WHO in April 2014. At the consultation, experts agreed that it would be 
important to pool the data and explore potential reasons for differences in trial results across 
sites.  The trial investigators convened a working group in September 2014 to develop the 
protocol and complete this meta-analysis. The analysis plan is available upon request. Since 
the meeting, results from a cluster randomized effectiveness trial conducted in Pakistan were 
published 25. The Pakistani investigators provided their data that have been included in the 
analyses.   
The objective of this paper is to present the findings on the efficacy of NVAS in reducing 
mortality under 6 months and under 12 months and how its effects may be modified by study 
population context characteristics in order to inform the development of public health 
recommendations. 
 
METHODS 
Potential studies for inclusion in the meta-analysis were identified through a systematic 
review that started with the examination of two published meta-analyses of NVAS.20,21 These 
reviews were updated using the Cochrane Central Register of Controlled Trials 
(CENTRAL)(The Cochrane Library), EMBASE, MEDLINE, clinical trials websites, 
conference proceedings, donor agencies, ’experts’ and researchers, the same search statement 
as in Gogia and Sachdev 2011 for identification of any additional randomized controlled 
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trials published between October 15, 2010 and February 22, 2016. Data from a further 
randomized controlled trial were included in the analysis after its publication in June 2016.25 
The primary outcomes were mortality from date of supplementation to six months and to 12 
months. The secondary outcome is to examine how its effects may be modified by study-
level and individual-level characteristics. The primary and secondary outcomes remain 
unchanged during the course of the study.  
 
Eligibility criteria and risk of bias assessment 
Individual or cluster randomized trials assessing the effect of early neonatal vitamin A 
supplementation (25,000 to 50,000 IU intended to be given within the first 2-3 days of life) 
compared to placebo, with infant follow up through at least 6 months of age, were eligible for 
inclusion in the meta-analysis. This excluded the West 1995 study as the period of 
supplementation extended beyond 3 days of life.10 
Risk of bias in the included studies was assessed following the Cochrane Handbook 
recommendations. 
Data collection process 
Investigators for each of the identified trials (except the Soofi S. et al trial25.) met in France in 
September 2014 to develop a harmonized pooled analysis protocol (not available in public 
domain), define subgroups of interest, and generate trial-specific estimates for each subgroup. 
The same protocol and definitions were used for the Pakistan trial data. For all trials effect 
sizes were provided as relative risks, except for Pakistan for which effects were expressed as 
odds ratios. 
Statistical methods 
The primary outcomes were mortality from date of supplementation to six months and to 12 
months. 
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To ensure comparability between studies, the effect size and corresponding 95% confidence 
intervals were non-parametrically calculated, using all randomized infants as the denominator 
for each individually randomized trial.  Effect sizes and 95% confidence intervals were 
calculated using generalized estimating equations (GEE) logistic regression model with log 
link and exchangeable correlation for the cluster randomized trials. Effect sizes were 
calculated for each study overall and for each of the specified subgroups.   
 
We assessed the magnitude of heterogeneity across studies with I2 statistics and 
corresponding p values.  We pooled the overall study specific point estimates using random 
effects models because of substantial  heterogeneity (I2  > 50, p for heterogeneity < 0.05) 
between studies. Subsequent subgroup analyses to explore potential sources of heterogeneity 
were conducted using fixed-effects meta-analysis. We compared subgroups using the X2 
statistical test for heterogeneity.    
 
Subgroup Analysis 
We performed bivariate meta-regression by study level characteristics to identify populations 
where the intervention may have differential effects. We defined ‘study level characteristics’ 
as the characteristics of the target populations of the studies. These included geographic 
region  (Africa or Asia); prevalence of maternal vitamin A deficiency which was assessed by 
study or extant data for a country or region, as there being none (0-1%) or mild  prevalence 
(2-9%) vs having a moderate (10-19%) or severely high (>20%) prevalence, adapting cut-offs 
from previous WHO guidance for assessing VAD in children 26,27; early infant mortality, i.e., 
mortality in the control group in the first 6 months of life (<30 per 1000 enrolled infants or 
>30 per 1000 enrolled infants); ratio of six month mortality to 12 month mortality in the 
control group (<75% or >75%); proportion of infants given the first DPT dose by six months 
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(<93% or >93%); and proportion of women who have never been to school (<32% or >32%).  
Maternal vitamin A moderate or severe status was defined as 10% or more women with 
serum retinol <0.7 mmol/L or 5% or more women with night blindness, according to the 
WHO Global Database on Vitamin A Deficiency 28. Thresholds to categorize mortality at six 
months, ratio of six-month to twelve-month mortality, proportion of infants given first DPT 
by six months, and the proportion of women who never attended school were established by 
using the median of the distribution of the characteristic in the total study population.  Meta-
analysis and meta-regression were performed in STATA (version 13). 
 
To further investigate potential sources of heterogeneity, we also performed subgroup 
analyses by a number of individual level characteristics.  Subgroups of interest included: 
infant sex (male or female); birth weight (<2500 grams or >2500 grams); gestational age and 
weight for gestational age categories (preterm-small-for-gestational-age, term-small-for-
gestational-age, preterm-average-for-gestational-age, or term-average-for-gestational-age), 
age at vitamin A supplementation (<24 hours, 24-47 hours, or  >48 hours), parity (1 child, 2-
3 children, or  >4 children), maternal education (none, primary school, secondary or more 
school), time of breastfeeding initiation (<1 hour, 2-23 hours, or >24 hours), colostrum given 
(yes or no), and maternal large-dose vitamin A supplementation (received or not received) 
and maternal serum retinol (<1.05 micromol/L, indicating low-to-deficient status or >1.05 
micromol/L, indicating adequate status). 
Patient involvement 
This manuscript uses data from published studies to address questions identified in 
consultation with public health researchers, clinicians, nutritionists. In the contributing 
studies, definition of intervention delivery and data collection opportunities considered 
patients’ practices and preferences. The intervention was delivered at a single contact with 
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the patient and was provided free of cost to families. Prior to study initiation, community 
leaders and families in the study areas were engaged by the teams that shared information and 
obtained participants’ consent. At the completion of the individual studies, consultations were 
held to disseminate findings and discuss their implications.  
RESULTS 
We included eleven studies from eight countries: Bangladesh, Ghana, Guinea-Bissau (3 
studies), India (2 studies), Indonesia, Pakistan, Tanzania, and Zimbabwe that met eligibility 
criteria. These trials included a total of 163,567 infants. Nine were individually randomized, 
and two were cluster randomized. Six individually randomized trials had two arms, NVAS 
(48,000 - 50,000 IU) and placebo.12,14,18,22-24  One individually randomized trial in Guinea 
Bissau among low birth weight infants had a factorial design and compared NVAS (25,000 
IU) to placebo plus early BCG vaccine or on-time BCG vaccine.17 A parallel, individually 
randomized trial in Guinea Bissau among normal birth weight infants was a 3-arm trial which 
compared NVAS (50,000 IU), NVAS (25,000 IU), and placebo.19 The individually 
randomized trial in Zimbabwe was a 2x2 factorial design comparing NVAS (50,000 IU), 
maternal vitamin A supplementation (400,000 IU), NVAS plus maternal supplementation, 
and placebo; results were published separately for mothers who were HIV-positive and HIV-
negative.15,16 The trial in Bangladesh was a cluster randomized trial nested within a maternal 
vitamin A supplementation (MVAS) trial, and infants were supplemented from birth up to 30 
days of age (median age at dosing 7 hours, [IQR: 2-18]).13 The trial in Pakistan was a cluster 
randomized trial that compared NVAS (50,000IU) to placebo delivered by local health 
staff.25 All identified published trials that met the intervention definition and reported on the 
primary outcome of this joint analysis were included. The risk of bias within included studies 
was determined to be low (Figure 1). Notably, half of the included trials published null 
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findings and selective reporting within studies was avoided by pooling the data specifically 
for purposes of this meta-analysis.  
 
STUDY CHARACTERISTICS 
Study characteristics are summarized in Web-Appendix A. Web-Appendix B provides 
information on the studies’ populations and individual level prevalence of the effect 
modifiers examined. 
 
RESULTS OF INDIVIDUAL STUDIES 
Four studies found reductions in infant mortality between supplementation with NVAS and 
six months12-14,22 and seven studies15-19,23-25 found no evidence of reduction.  Regarding the 
effect of NVAS on mortality through 12 months, two studies found reductions in 
mortality12,13, while the remaining eight studies found no evidence of reduction. One trial did 
not follow up infants beyond 6 months of age.14  
 
SYNTHESIS OF RESULTS  
Overall pooled analysis 
After pooling the eleven trials which reported mortality risk at six months, there was no 
evidence of a reduced risk of death; the pooled rates ratio (RR) based on a random effects 
model was 0.97; 95% CI 0.89-1.06 (Table 1 and Figure 2).   
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Table 1. Results from univariate meta-regression and meta-analysis pooled rates rations for the effect of neonatal vitamin A supplementation against a placebo on 
mortality (random effects) 
 Mortality < 6 months Mortality < 12 months 
Study-Level Characteristic Na  Included Studiesb RR (95% CI) 
Meta-
Regression  
p value 
Na  Included Studiesb RR (95% CI) 
Meta-
Regressionc  
p value 
Overall 11 a- k RE 0.97 (0.89-1.06)  10 a-h,j,k RE 1.00 (0.93-1.08)  
Geographic Region 
 Asia 5 a,f,i,j,k RE 0.87 (0.77-0.98) 
0.009 
  
4  a,f,j,k RE 0.91 (0.80-1.03) 
 
 
0.013 
  Africa 6 b,c,d,e,g,h RE 1.06 (0.98-1.15) 
  
6 b,c,d,e,g,h RE 1.07 (1.00-1.15) 
Maternal vitamin A deficiency level   
   
      
 
  moderate/severe 3 a,f,i RE 0.87 (0.80-0.94) 
 
0.012 
  
2 a,f RE 0.91 (0.83-1.00) 
 
0.033 
  none/mild 7 b,c,d,e,g,h,j RE 1.05 (0.96-1.15) 
  
7 b,c,d,e,g,h,j RE 1.06 (0.98-1.15) 
Maternal postnatal vitamin A program     
   
      
 
  no  7 a,d,e,g,i,j,k 
RE 0.93 (0.82-1.05) 
0.392 
  
6 
a,d,e,g,j,k  RE 0.99 (0.88-1.12)  
0.768 
 
  yes 4 b,c,f,h 
RE 1.00 (0.89-1.13) 
  
4 
b,c,f,h RE 1.02 (0.91-1.13) 
Mortality enrolment to 6 months (control gp)   
   
      
 
  >30 / 1000 6 a,e,f,h,i,k RE 0.91 (0.85-0.98) 
 
0.021 
  
5 a,e,f,h,k RE 0.97 (0.89-1.04) 
 
0.181 
 
<30 / 1000 5 b,c,d,g,j RE 1.08 (0.95-1.24) 
  
5 b,c,d,g,j RE1.06 (0.93-1.22) 
Ratio of mortality 6 to 12 mo     
   
      
 
  >75% 6 a,e,f,h,j,k RE 0.92 (0.84-1.01) 
 
0.019 
  
6 a,e,f,h,j,k RE 0.96 (0.86-1.06) 
 
0.065 
  <75% 4 b,c,d,g RE 1.11 (1.00-1.22) 
  
4 b,c,d,g  RE 1.08 (0.99-1.17) 
Proportion given first DPT by 6 months   
   
      
 
  <93% 4 a,e,I,k 
 
RE 0.91 (0.82-1.00)  
0.209 
  
3 
a,e,k 
 
RE 0.96 (0.89- 1.03)  
0.640 
  >93% 5 b,c,d,f,g  
RE 1.03 (0.91-1.18) 
  
5 
b,c,d,f,g 
 
RE 1.03 (0.91-1.15) 
13 
 
13 
 
 
Proportion of mothers with no schooling 
 
   
  
  
     
  >32% 4 a,f,g,i RE 0.88 (0.80-0.96) 
 
0.041 
  
3 a,f,g 
 
RE 0.93-0.85-1.01) 
 
0.083 
  <32% 5 b,c,d,h,j 
 
1.04 (0.92-1.18) 
  
5 b,c,d,h,j RE 1.06 (0.95-1.18) 
a   - Number of studies included in subgroup analysis 
b -  Studies are noted as follows: a) Mazumder (2014);  b) Edmond (2014);  c) Masanja (2014);  d) Benn (2014);  e) Benn (2010); f) Klemm (2008);  g) Benn (2008);  h) Malaba (2005) 
& Humphrey (2006);  i) Rahmathullah (2003);  j) Humphrey (1996); k) Soofi (2016) 
c -  p-value from univariate meta-regression 
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After combining data from the ten trials which reported mortality by 12 months, there was 
also no evidence of a reduced risk of death; the pooled rates ratio calculated with a random 
effects model was 1.00; 95% CI 0.93-1.08 (Figure 3). 
Pooled results stratified by study-level characteristics 
Using meta-regression, we identified five variables as significantly associated with the effect 
of NVAS on mortality at six months: geographic region of study, prevalence of maternal 
vitamin A deficiency, control group mortality at 6 months, ratio of six-month to twelve-
month mortality, and proportion of mothers with no schooling. Geographic region and 
prevalence of maternal vitamin A deficiency were associated with the effect of NVAS on 
mortality by 12 months (Table 1).  
 
Geographic region 
 Based on the five trials conducted in Asia, NVAS was associated with a 13% lower risk of 
death until six months (RR 0.87; 95% CI 0.77-0.98). In Africa, based on six trials, the 
intervention was associated with higher, but not statistically significant, risk of death (RR 
1.06; 95% CI 0.98-1.15).  Based on four trials in Asia which followed infants through 12 
months, NVAS was associated with a 9% lower risk of infant death (RR 0.91; 95% CI 0.80-
1.03), but this was not statistically significant. In Africa, based on six trials, NVAS was 
associated with 7% higher risk of death through 12 months (RR 1.07; 95% CI 1.00-1.15).  
 
Maternal vitamin A deficiency 
NVAS was associated with 13% lower mortality to 6 months in the pooled results from three 
trials conducted in study populations where the prevalence of maternal vitamin A deficiency 
was moderate/severe (RR 0.87; 95% CI 0.80-0.94), but not in the pooled results from seven 
trials conducted in study populations with no or mild deficiency (RR 1.05; 95% CI 0.96-
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1.15). We observed similarly contrasting results regarding mortality through 12 months. In 
study populations where the prevalence of maternal vitamin A deficiency was moderate or 
severe, two trials observed a 9% reduction in mortality (RR 0.91; 95% CI 0.83-1.00); in the 
seven study populations with no or mild maternal deficiency, mortality was 6% higher but 
this was not statistically significant (RR 1.06; 95% CI 0.98-1.15).   
 
Control group mortality at 6 months and ratio of mortality to 6 and 12 months Among 
six trials conducted in study populations where six months mortality in the control group was 
30 or more per 1000 live births, we found a 9% lower risk of death up to 6 months of age 
with NVAS (RR 0.91 CI% 0.85-0.98); but we found a non-significant 8% higher risk of death 
among the five trials conducted in populations where six months mortality in the control 
group was under 30/1000 (RR 1.08; 95% CI 0.95-1.24). Further, among six trials conducted 
in populations where 75% or more of infant mortality occurred in the first six months, there 
was evidence of lower mortality associated with NVAS (RR 0.92; 95% CI 0.84-1.01), but 
this was not statistically significant.  The opposite was seen among four trials conducted in 
populations where less than 75% of infant mortality occurred in the first six months (RR 
1.11; 95% CI 1.00-1.22). 
 
Maternal education 
Among four trials conducted in study populations where the >32% of mothers had never been 
to school, we found a 12% lower risk of death in the first 6 months of life with NVAS (RR 
0.88; 95% CI 0.80-0.96); but we found no difference in the risk of death among the five trials 
conducted in populations where <32% of mothers had never been to school (RR 1.04; 95% 
CI 0.92-1.18).  
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Pooled results stratified by individual-level characteristics 
Meta-analyses of effects of NVAS at 6 and 12 months stratified by eleven individual level 
characteristics (sex, birth weight, size for gestation, age at dosing, parity, maternal education, 
time of breastfeeding initiation, colostrum given, maternal vitamin A supplementation and 
maternal night blindness) did not show any significant heterogeneity between subgroups. The 
only exception was stratification by maternal serum retinol at baseline, which showed 
significant heterogeneity (p=0.042) in effects of NVAS among infants born to mothers with 
low-to-deficient (RR 0.73; 95% CI 0.51-1.05) and adequate status (RR 1.26; 95% CI 0.86-
1.84), thus suggesting effect modification. However, the rates ratio was not significant in 
either of the two subgroups (Table 2). 
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Table 2. Meta-analysis pooled rates rations for the effect of neonatal vitamin A supplementation against a placebo on mortality through six month and through 12  
months, overall and stratified by individual-level subgroups (fixed effects) 
    Mortality <6 months   Mortality <12 months 
Individual-Level 
Characteristic 
N  
Studies 
Included 
Studies* RR (95% CI) I
2
 (p value) p value of test of heterogeneity   
N  
Studies 
Included 
Studies* RR (95% CI) I
2
 (p value) p value of test of heterogeneity 
Overall 11 a- k 0.97 (0.89-1.06) 49.4 (0.03)     10 a-h,j,k 1.00 (0.93-1.08) 46.3 (0.05)   
Sex                       
  Male 11 a-k 0.99 (0.92-1.08) 49.0 (0.03) 0.255   10 a-h,j,k 1.00 (0.93-1.07) 46.6 (0.05) 0.760 
  Female 0.93 (0.86-1.01) 26.5 (0.19)   0.99 (0.92-1.06) 42.8 (0.07) 
Birthweight                       
  <2500 g 8 a,b,c,f, h,i,j,k 
0.97 (0.89-1.05) 52.0 (0.04) 0.895   7 a,b,c,f, h,j,k 
0.99 (0.92-1.08) 36.9 (0.15) 0.964 
  >2500 g 0.96 (0.89-1.04) 44.8 (0.08)   1.00 (0.93-1.07) 34.6 (0.16) 
Size for Gestation Age    
 
      
    
      
  Preterm SGA 
6 a,c,f,h,i,j 
1.09 (0.86, 1.39) 29.6 (0.21) 
0.294 
 
5 a,c,f,h,j 
1.14 (0.90- 1.45) 4.1 (0.38) 
0.354   Preterm AGA 0.94 (0.81-1.08) 27.7 (0.24)  0.95 (0.83- 1.09) 0.0 (0.54) 
  Term SGA 0.87 (0.78-0.97) 21.1 (0.28)  0.92 (0.83-1.02) 3.6 (0.39) 
  Term AGA 0.98 (0.87, 1.10) 0.0 (0.88)  1.00 (0.91, 1.10) 0.0 (0.95) 
Age at Dosing                       
  <24 hours 
11 a-k 
0.99 (0.92-1.06) 31.6 (0.15) 
0.594 
  
10 a-h,j,k 
0.99 (0.93-1.05) 25.2 (0.21) 
0.682 
  24-47 hours 0.93 (0.83-1.04) 32.0 (0.14)   1.03 (0.93-1.14) 28.0 (0.19) 
  >48 hours 0.93 (0.77-1.12) 0.0 (0.75)   0.94 (0.79-1.12) 0.0 (0.94) 
Parity                       
  1 child 
11 a-k 
0.91 (0.83-1.00) 13.3 (0.32) 
0.338 
  
10 a-h,j,k 
0.96 (0.88-1.04) 0.0 (0.46) 
0.308 
  2-3 children 1.00 (0.92-1.09) 0.0 (0.64)   1.05 (0.97-1.13) 3.5 (0.41) 
  >4 children 0.97 (0.86-1.09) 44.9 (0.05)   0.98 (0.89-1.09) 48.4 (0.04) 
Maternal Schooling                       
  none 
9 a-i 
0.95 (0.86-1.05) 53.4 (0.03) 
0.782 
  
8 a-h 
0.96 (0.88-1.05) 43.7 (0.09) 
0.611 
  primary school 0.98 (0.88-1.09) 6.2 (0.38)   1.02 (0.93-1.11) 0.0 (0.73) 
  secondary school or more 0.93 (0.85-1.02) 16.9 (0.29)   1.00 (0.92-1.09) 53.2 (0.03) 
Time of Breastfeeding 
Initiation                       
  <=1 hour 
6 a,b,c,f,h,k 
1.03 (0.94-1.14) 63.2 (0.02) 
0.339 
  
6 a,b,c,f,h,k 
1.03 (0.95-1.12) 55.8 (0.04) 
0.313 
  2-23 hours 0.94 (0.87-1.03) 0.0 (0.71)   0.97 (0.90-1.05) 0.0 (0.65) 
  >24 hours 0.92 (0.74-1.13) 0.0 (0.67)   0.90 (0.74-1.08) 0.0 (0.69) 
Colostrum Given                       
  yes 7 a,b,c,f,h,i,k 0.96 (0.90-1.0) 47.2 (0.08) 0.974   6 a,b,c,f,h,k 1.00 (0.94-1.05) 35.4 (0.17) 0.860 
  no  0.96 (0.82-1.13) 0.0 (0.47)   0.98 (0.84-1.14) 0.0 (0.52) 
Maternal Vitamin A 
Supplementation                       
  yes 4 b,c,f,h 0.97 (0.88-1.08) 58.8 (0.06) 0.273   4 b,c,f,h 1.00 (0.92-1.09) 62.3 (0.05) 0.505 
  no 1.06 (0.94-1.19) 27.2 (0.25)   1.05 (0.95-1.16) 72.2 (0.01) 
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Maternal Night Blindness                       
  yes 3 f,i,k 0.93(0.65-1.33) 0.0 (0.49) 0.660   2 f,k 0.94 (0.64-1.37) 30.0 (0.23) 0.765 
  no 0.86 (0.77-0.96) 58.3(0.09)   0.88 (0.78-1.00) 70.8 (0.06) 
Maternal serum retinol level                       
  < 1.05 micromol/L 3         a, f, h 0.73 (0.51, 1.05) 0.0 (0.51) 0.042   3 a, f, h 0.82 (0.60-1.13) 0.0 (0.54) 0.067 
  ≥1.05 micromol/L 1.26 (0.86-1.84) 0.0 (0.84)   1.26 (0.90-1.77) 0.0 (0.75) 
             
             
*Studies are noted as follows: a) Mazumder (2014);  b) Edmond (2014);  c) Masanja (2014);  d) Benn (2014);  e) Benn (2010); f) Klemm (2008);  g) Benn (2008);  h) Malaba (2005) & Humphrey (2006);  i) 
Rahmathullah (2003);  j) Humphrey (1996); k) Soofi (2016 
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While there was no indication that size for gestation and maternal night blindness are significant effect 
modifiers, two individual subgroups by these characteristics showed significant effects.  NVAS significantly 
reduced the risk of death under six months among term-small-for-gestational-age infants (RR 0.86; 95% CI 
0.77-0.97) but not among other subgroups by size and gestation in pooled results from six studies. NVAS 
also significantly reduced risk of death by six months in four studies among infants of mothers who reported 
no night blindness (RR 0.90; CI 95% 0.82-0.98), but not significantly so in mothers who reported night 
blindness (RR 0.89; CI 95% 0.64-1.26) (Table 2).  
 
There was no significant benefit or harm identified for any of the subgroups by individual level 
characteristics regarding mortality through 12 months (Table 2).  Web-Annex C provides information on the 
estimates of the effects of NVAS on 6 and 12 month mortality for each study in the subgroups. 
 
 
 
DISCUSSION  
The pooled effect estimates from all studies indicate that neonatal vitamin A supplementation had no overall 
benefit in reducing mortality through six or twelve months of age. A similar finding was reported by Haider, 
Sharma and Bhutta in their 2017 systematic review 29.However, there was significant heterogeneity, 
suggesting that the effects of NVAS on survival are influenced by study population characteristics.  
 
Most studies conducted in Asia showed benefits for survival (RR 0.87; 95% CI 0.77-0.98) in the first six 
months of life, but no significant effect at twelve months (RR 0.91; 95% CI 0.80-1.03). In Africa, however, 
none of the studies showed benefits, and the overall results could not rule out the possibility of it causing 
harm (RR 1.06, 95% CI 0.98-1.15 for the first six months; and RR 1.07; 95% CI 1.00-1.15 for the first 
twelve months).  
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We propose that geography is a marker of differences in study population contexts. In Asia, studies were 
conducted in populations with a higher prevalence of maternal vitamin A deficiency, higher early infant 
mortality, higher proportion of infant deaths within the first 6 months of life, and lower levels of maternal 
schooling. In Africa, on the other hand, study populations lived in contexts that had a lower prevalence of 
maternal vitamin A deficiency, lower infant mortality, lower early proportion of infant deaths in the first six 
months, and higher levels of maternal schooling.  The differences in observed effects of NVAS between the 
two continents are likely to reflect, to some extent, the underlying differences in the contexts where 
populations were studied.  
 
 
We found that neonatal vitamin A supplementation reduced mortality in populations classified as having a 
moderate/severely high prevalence of maternal vitamin A deficiency, defined as 10% or higher proportion of 
women with serum retinol <0.7 mmol/L or 5% or more women with night blindness.  Notably, all the 
studied populations meeting this prevalence thresholds were in Southern Asia. This finding was partially 
supported by meta-analysis using individual-level characteristics, which suggested that baseline maternal 
retinol level may be an effect modifier for the effect of NVAS. However, maternal night blindness at 
individual level did not modify the effect of NVAS, as maternal night blindness was  treated when detected 
during pregnancy in the trials.    
 
We observed that studies conducted in contexts with higher early infant mortality showed a significant 
benefit of NVAS, an observation already made by Haider and Bhutta in their 2011 systematic review20.  The 
mechanisms underlying this effect of NVAS on mortality are unclear. There are plausible ways through 
which NVAS could reduce severity of infection and mortality. Neonates in undernourished populations tend 
to be vitamin A deficient by conventional plasma indicators.30  In South India, where newborn vitamin A 
supplementation lowered mortality by 22% 14, case fatality from diarrhoea and fever was reduced by 40-
50% during the first six months 31, possibly reflecting antioxidant and anti-inflammatory roles of vitamin A 
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in preserving intestinal tract defences.32-34  In the same study, newborn vitamin A also halved the risk of 
incident nasopharyngeal pneumococcal colonization from 2 to 4 months of age 35, suggestive of 
strengthened postnatal respiratory defences.  An alternative mechanism, suggested in published literature, 
that may explain the differences in Asia and Africa is that NVAS has harmful effects in females  after they 
receive DPT vaccine, and the proportion of infants who receive DPT vaccine on time was higher in African 
study sites.36 
 
Meta-analyses by individual-level characteristics that could be proxies for infant vitamin A status did not 
support the hypothesis that NVAS efficacy is modified by maternal or newborn baseline vitamin A status. 
Low birth weight infants and pre-terms infants in this analysis, either appropriate or small for gestational 
age, who would have lower vitamin A stores than their normal birthweight and term peers 37,38, did not show 
benefit from NVAS. We acknowledge, nonetheless, that the data on gestational age had limitations.  
Similarly, we did not find a significant benefit of NVAS among infants whose mothers had not received 
post-partum maternal vitamin A supplementation.  However, the validity of post-partum maternal vitamin A 
supplementation programmes as a proxy for maternal vitamin A status is not clear, as it may depend on a 
mother’s pre-existing level of vitamin A deficiency and quality of programme implementation. In fact, a 
subgroup analysis among participants in the Tanzania trial found that the effect of NVAS was modified by 
both postpartum maternal vitamin A supplementation and the amount of vitamin A that women consumed 
through food.39 
We must acknowledge that the associations derived from meta-regressions are observational, and do not 
have the strength of causal relationships derived from randomized comparisons. This has been noted to 
apply particularly when averages of patient characteristics in each trial are used as covariates in the 
regression.  We must also acknowledge that  we conducted many subgroup analyses, and some of the 
significant differences between subgroups may have occurred by chance.  
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There are many strengths of this analysis. We included data from all published trials of NVAS, bringing 
together information from over 160,000 newborns in 8 different countries.  The trial-specific subgroup 
analysis was conducted by the investigators themselves following a jointly agreed upon plan using 
individual data records. Study-specific relative risks for each subgroup were calculated using the same 
definitions and methods for every study, ensuring that observed heterogeneity was not due to analytical 
differences in the way the effect estimates were calculated. One major limitation is that we lack individual-
level data on the maternal vitamin A status for most mothers in the trials. Such data would have allowed us 
to better examine the hypothesis that the efficacy of NVAS is modified by maternal vitamin A status. 
Although five studies assessed serum retinol in a subset of subjects, due to the small sample sizes for each 
study there was insufficient power to conduct a subgroup analysis based on these data in two of these five 
studies. We did consider analysing continuous data in meta-regression but did not take this approach as data 
points were very few. 
 
Our pooled analyses reveal the absence of an overall benefit of NVAS on mortality, but show substantial 
heterogeneity in the effect. This heterogeneity is best explained by the characteristics of study populations’ 
contexts, suggesting that NVAS is beneficial in South Asian contexts where the prevalence of maternal 
vitamin A deficiency is moderate to severe, early infant mortality is high (exceeding 30 deaths per 1000 live 
births), and maternal schooling is low.  On the other hand, no benefit to survival, and even a possibility of 
harm, is observed in African contexts where maternal vitamin A deficiency is absent or only a mild public 
health concern, infant mortality is lower, and levels of maternal schooling are higher.   
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